Registry study on factors predicting outcomes in aneurysmal subarachnoid hemorrhage

Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal Subarachnoid Hemorrhage

This study is trying to find out what factors can help predict how well people with aneurysmal subarachnoid hemorrhage will do after their condition and improve how they are treated.

Quick facts

• Study type: Observational
• Enrollment: 5000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Second Affiliated Hospital of Nanchang University (Academic / other)
• Locations: 1 site (Nanchang, Jiangxi)
• Trial ID: NCT05738083 on ClinicalTrials.gov

What this trial studies

PROSAH-MPC is a collaborative research project involving multiple neurosurgical centers in China that aims to identify prognostic factors and develop prediction models for complications, disability, and mortality in patients with aneurysmal subarachnoid hemorrhage (aSAH). The study utilizes a large, multi-center, prospective cohort design to gather extensive clinical and radiological data, including demographics, medical histories, and imaging features. By employing machine learning techniques, the study seeks to extract critical predictive features from imaging data, enhancing the accuracy of the developed models. This comprehensive approach aims to provide a better understanding of aSAH outcomes and improve patient management.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with subarachnoid hemorrhage due to a ruptured intracranial aneurysm who meet specific clinical criteria.

Not a fit: Patients with aneurysm rupture bleeding for more than 24 hours before hospital admission or those with incomplete imaging or blood test data may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved prediction of complications and outcomes for patients with aneurysmal subarachnoid hemorrhage.

How similar studies have performed: Other studies have shown success in using multi-center approaches and machine learning for predicting outcomes in similar conditions, indicating a promising avenue for this research.

Eligibility criteria

Inclusion Criteria:

* Subarachnoid hemorrhage confirmed by computed tomography (CT);
* Cerebral angiography (CTA) and digital subtraction angiography (DSA) examination confirming intracranial aneurysm rupture as the cause of the subarachnoid hemorrhage;
* Blood routine, biochemical function, blood coagulation function, and craniocerebral CT performed within 24 hours of symptom onset;
* Underwent aneurysm clipping by surgery or endovascular embolization within 72 hours after-onset.

Exclusion Criteria:

* Aneurysm rupture bleeding time exceeding 24 hours before hospital admission;
* Incomplete image data or blood test information;
* Long-term use of anticoagulant medications such as aspirin or warfarin;
* Admitted to hospital with active infectious diseases;
* long-term anticoagulant drugs such as aspirin, wave dimensions;
* Presence of other intracranial vascular malformations.

Where this trial is running

Nanchang, Jiangxi

• The Second Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China (Recruiting)

Study contacts

• Principal investigator: Qianxue Chen, Prof — Renmin Hospital of Wuhan University
• Study coordinator: Xingen Zhu, Prof

Conditions Aneurysmal Subarachnoid Hemorrhage